A sign for the Food and Drug Administration is displayed outside their offices in Silver Spring, Md., on Dec. 10, 2020. (AP Photo/Manuel Balce Ceneta, File)
U.S. health officials are alerting consumers about two more recalls of eyedrops due to contamination risks that could lead to vision problems and serious injury.
The announcements follow a recall last month of eyedrops made in India that were linked to an outbreak of drug-resistant infections. One person died and at least five others had permanent vision loss.
There's no indication the latest recalls are related to those products.
The Food and Drug Administration posted separate recall notices for certain eyedrops distributed by Pharmedica and Apotex after the companies said they are voluntarily pulling several lots of their products from the market. Both companies said the recalls were conducted in consultation with the FDA.
Pharmedica on Friday said it is recalling two lots of Purely Soothing 15% MSM Drops due to problems “that could result in blindness." The over-the-counter drops are designed to treat eye irritation. The Phoenix-based company said consumers should immediately stop using the drops and return them to the place they were purchased.
The recall affects nearly 2,900 bottles, according to the company. The drops were manufactured in Arizona.
Last week, the FDA posted a separate recall announcement from Apotex recalling six lots of prescription eyedrops used to treat a form of glaucoma. The company said it launched the recall after finding cracks in a handful of bottle caps.
The drops are distributed as Brimonidine Tartrate Ophthalmic Solution. 0.15% and were sold between last April through February.
Apotex said in an email that the eyedrops were manufactured in Canada. The company hasn't received any reports of injuries related to the drops.
___
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Science and Educational Media Group. The AP is solely responsible for all content.
The list of questions should be getting shorter as we enter the pandemic's third year, but that isn't the case. There's another question to add to that list: is the U.S. doing enough to track the virus and its variants? Lawrence Gostin, faculty director of the O'Neill Institute for national and global health law at Georgetown University, joins Cheddar News.
As we prepare to ring in the new year, COVID cases are hitting an all-time high. Dr. Anthony Fauci has said the safest way to celebrate would be a small gathering with vaccinated family members only... far from the large, flashy parties from a few years ago. Dr. Christina Johns, senior medical advisor at PM Pediatrics, joins Cheddar News to discuss how to celebrate safely.
Jurors in the trial against Theranos CEO Elizabeth Holmes have entered day six of deliberations. Holmes is accused of lying to investors about the functionality of a newly developed blood-testing technology. Andrew George, partner at Baker Botts, joined Cheddar to break down key points in the case and what the jury might be considering during their deliberations. He also noted that the rest of Silicon Valley, including Holmes' business partner, Ramesh "Sunny" Balwani, who is facing identical charges, is closely watching the outcome of deliberations — as it could set the tone for future regulations and Balwani's own trial.
According to researchers, the state of California's cap-and-trade program is currently being undermined by forest fires caused primarily by climate change. Over the past few years, trees that were set aside for the program have been releasing carbon as they continue to burn in fires. Climate Researcher and Policy Director at CarbonPlan Danny Cullenward, joined Cheddar to discuss more.
The CDC's latest update to its COVID-19 quarantine guidelines reduces the isolation period from ten days to just five for people who test positive but are asymptomatic. Dr. Bayo Curry-Winchell, regional clinical director at Carbon Health, spoke to Cheddar's Baker Machado about the new guidance. She noted that while the reduced quarantine time "makes sense," the CDC should also require that a person test negative after their quarantine and before interacting with the public. "There is science behind it. We know that the majority of illness happens, or transmission, one to two days before the onset of symptoms and then two to three days as you have symptoms. So there is science behind the reducement of the actual five days," she said.
